<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02037035</url>
  </required_header>
  <id_info>
    <org_study_id>1305011972</org_study_id>
    <secondary_id>1K23MH101498-01</secondary_id>
    <nct_id>NCT02037035</nct_id>
  </id_info>
  <brief_title>Examining The Effect Of Ketamine On Glutamate/Glutamine Cycling</brief_title>
  <official_title>Examining The Effect Of Ketamine On Glutamate/Glutamine Cycling</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>American Psychiatric Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is looking at the mechanisms underlying the behavioral effects of ketamine in&#xD;
      healthy and depressed individuals.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">June 2021</completion_date>
  <primary_completion_date type="Actual">June 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glutamate Metabolism</measure>
    <time_frame>40-75 minutes</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy participants will receive ketamine in the scan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Depressed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Depressed participants will receive ketamine in the scan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <arm_group_label>Depressed</arm_group_label>
    <arm_group_label>Healthy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Healthy Group&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female between the ages of 21-65 years.&#xD;
&#xD;
          -  Able to provide written informed consent.&#xD;
&#xD;
          -  Able to read and write English.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Personal or first-degree family member with history of mood, anxiety, or psychotic&#xD;
             axis I DSM-IV disorders confirmed after comprehensive psychiatric evaluation.&#xD;
&#xD;
          -  Any history of serious medical or neurological illness.&#xD;
&#xD;
          -  Any signs of major medical or neurological illness on examination or as a result of&#xD;
             ECG screening or laboratory studies.&#xD;
&#xD;
          -  Lifetime history of psychoactive substance or alcohol dependence or substance or&#xD;
             alcohol abuse (other than nicotine or caffeine abuse), or drinking more that 5&#xD;
             drinks/week during the last year.&#xD;
&#xD;
          -  Abnormality on physical examination.&#xD;
&#xD;
          -  A positive pre-study (screening) urine drug screen or, at the study physician's&#xD;
             discretion on any drug screens given before the scans.&#xD;
&#xD;
          -  Pregnant or lactating women or a positive urine pregnancy test for women of&#xD;
             child-bearing potential at screening or prior to any imaging day.&#xD;
&#xD;
          -  Subjects who test positive for HIV or viral hepatitis (hepatitis B and/or C)&#xD;
&#xD;
          -  Has received either prescribed or over-the-counter (OTC) centrally active medicine or&#xD;
             herbal supplements within the week prior to the MRI scan.&#xD;
&#xD;
          -  Any history indicating learning disability, mental retardation, or attention deficit&#xD;
             disorder.&#xD;
&#xD;
          -  Known sensitivity to ketamine.&#xD;
&#xD;
          -  Body circumference of 52 inches or greater.&#xD;
&#xD;
          -  Body weight of 280 pounds or greater.&#xD;
&#xD;
          -  History of claustrophobia.&#xD;
&#xD;
          -  Presence of cardiac pacemaker or other electronic device or ferromagnetic metal&#xD;
             foreign bodies in vulnerable positions as assessed by a standard pre-MRI screening&#xD;
             questionnaire.&#xD;
&#xD;
          -  Donation of blood in excess of 500 mL within 56 days prior to dosing.&#xD;
&#xD;
          -  History of sensitivity to heparin or heparin-induced thrombocytopenia.&#xD;
&#xD;
          -  Resting blood pressure lower than 90/60 or higher than 150/90,or resting heart rate&#xD;
             lower than 45/min or higher than 100/min.&#xD;
&#xD;
        Depression Group&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female between the ages of 21-65 years.&#xD;
&#xD;
          -  Able to provide written informed consent.&#xD;
&#xD;
          -  Current MDD Single Episode (296.2x) or Recurrent (296.3x), as determined by the&#xD;
             Structured Clinical Interview for DSM-IV (SCID) patient edition&#xD;
&#xD;
          -  Montgomery Asberg Depression Rating Scale (MADRS) score of 18 or higher at baseline&#xD;
             and start of first 13C-MRS.&#xD;
&#xD;
          -  Quick Inventory of Depressive Symptoms - Self-Report (QIDS-SR16) score of 19 or higher&#xD;
             at baseline and start of first 13C-MRS.&#xD;
&#xD;
          -  No psychotropic medications for 2 or more weeks (4 weeks for Fluoxetine) prior to&#xD;
             first 13C-MRS.&#xD;
&#xD;
          -  Be able to understand and speak English.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a history of DSM-IV-TR diagnosis of bipolar disorder or schizophrenia or&#xD;
             schizoaffective disorder or currently exhibiting psychotic features associated with&#xD;
             their depression; dementia or suspicion thereof, is also exclusionary.&#xD;
&#xD;
          -  First-degree family member with history of schizophrenia or any other psychotic&#xD;
             disorder.&#xD;
&#xD;
          -  Serious suicide or homicide risk, as assessed by evaluating clinician; A serious&#xD;
             suicide risk will be considered an inability to control suicide attempts, imminent&#xD;
             risk of suicide in the investigator's judgment, or a history of serious suicidal&#xD;
             behavior, which is defined using the Columbia-Suicide Severity Rating Scale (C-SSRS)&#xD;
             as either (1) one or more actual suicide attempts in the 3 years before study entry&#xD;
             with the lethality rated at 3 or higher, or (2) one or more interrupted suicide&#xD;
             attempts with a potential lethality judged to result in serious injury or death.&#xD;
&#xD;
          -  Substance abuse or dependence during the 12 months prior to screening.&#xD;
&#xD;
          -  Any history of serious medical or neurological illness.&#xD;
&#xD;
          -  Any signs of major medical or neurological illness.&#xD;
&#xD;
          -  Abnormality on physical examination. A subject with a clinical abnormality may be&#xD;
             included only if the study physician considers the abnormality will not introduce&#xD;
             additional risk factors and will not interfere with the study procedure.&#xD;
&#xD;
          -  A positive pre-study (screening) urine drug screen or on any drug screens given before&#xD;
             the scans.&#xD;
&#xD;
          -  Pregnant or lactating women or a positive urine pregnancy test for women of&#xD;
             childbearing potential at screening or prior to any imaging day.&#xD;
&#xD;
          -  Any history indicating learning disability, or mental retardation.&#xD;
&#xD;
          -  Known sensitivity to ketamine.&#xD;
&#xD;
          -  Body weight of 280 pounds or greater.&#xD;
&#xD;
          -  History of claustrophobia.&#xD;
&#xD;
          -  Presence of cardiac pacemaker or other electronic device or ferromagnetic metal&#xD;
             foreign bodies in vulnerable positions as assessed by a standard pre-MRI screening&#xD;
             questionnaire.&#xD;
&#xD;
          -  Donation of blood in excess of 500 mL within 56 days prior to dosing.&#xD;
&#xD;
          -  History of sensitivity to heparin or heparin-induced thrombocytopenia.&#xD;
&#xD;
          -  Resting blood pressure lower than 90/60 or higher than 150/90,or resting heart rate&#xD;
             lower than 45/min or higher than 100/min.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lynnette Averill, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale Depression Research Program</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 19, 2013</study_first_submitted>
  <study_first_submitted_qc>January 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2014</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

